Attorney Michael Lin Baum, has dedicated his career to protecting consumers from the negligence and wrongdoing of major pharmaceutical companies and commercial transportation firms. As managing partner and the lawyer heading up the pharmaceutical litigation team at the Los Angeles firm of Baum Hedlund Aristei & Goldman, he has brought hundreds of successful suits against numerous pharmaceutical firms from around the world. Michael Lin Baum and his team, helped uncover the link between SSRI antidepressants and heart birth defects. Over the past few years, he has been an instrumental figure in the litigation against the makers of Paxil, Prozac, and other major antidepressant manufacturers.

Mr. Baum’s efforts in the pharmaceutical field have helped initiate significant changes in the industry. He has played an important role in the implementation of safety measures such as the “black box” warnings that now appear on most antidepressants, and his work helped drive the Ricky Ray Hemophilia Relief Fund Act of 1998. As a result of his reputation in the field, government and consumer authorities from countries around the world, including Ireland, Taiwan, and Russia, have sought his expertise as an attorney in this area of law when developing public health and consumer protection policy.

Mr. Baum holds a bachelor’s degree and juris doctor from the University of California, Los Angeles. A prominent lawyer, he is a member of the Consumer Attorneys of California, the Leader’s Forum of the American Association for Justice, and many other professional organizations.